封面
市場調查報告書
商品編碼
1630740

疼痛管理治療市場規模、佔有率、成長分析(按藥物類別、適應症、分銷管道和地區分類)- 產業預測,2025 年至 2032 年

Pain Management Therapeutics Market Size, Share, Growth Analysis, By Drug Class (NSAIDs, Anesthetics), By Indication (Arthritic Pain, Neuropathic Pain), By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 276 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2023 年全球疼痛管理治療市場規模價值為 787 億美元,預計將從 2024 年的 815.3 億美元成長到 2032 年的 1,082 億美元,預測期內(2025-2032 年)的複合年成長率為 3.6%。

截至 2023 年 10 月,疼痛管理領域反映出人們越來越認知到其在醫學領域的重要性。越來越多的醫生開始求助於疼痛醫學專家來實施多學科方法來改善患者多種疼痛的生活品質,包括纖維肌痛、神經病變疼痛和術後不適等慢性病。疼痛管理治療越來越受歡迎,因為它們可以解決廣泛的醫療問題。然而,由於政府預算削減和藥品贊助商支持減少,疼痛倡導團體的影響力和財力資源減少,市場也面臨挑戰。由於這些組織歷來在推動疼痛管理舉措方面發揮關鍵作用,因此這一趨勢對市場成長構成了潛在的障礙。

目錄

介紹

  • 調查目的
  • 研究範圍
  • 定義

調查方法

  • 資訊採購
  • 次要和資料資料
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 全球市場展望
  • 供需趨勢分析
  • 細分市場機會分析

市場動態及展望

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進因素和機遇
    • 限制與挑戰
  • 波特的分析

主要市場考察

  • 關鍵成功因素
  • 競爭程度
  • 主要投資機會
  • 市場生態系統
  • 市場吸引力指數(2024 年)
  • PESTEL 分析
  • 總體經濟指標
  • 價值鏈分析
  • 定價分析
  • 監管格局
  • 案例研究
  • 技術分析
  • 專利分析

疼痛管理治療市場規模(依藥物類別)

  • 市場概況
  • NSAIDs
  • 麻醉劑
  • 抗驚厥藥
  • 偏頭痛藥物
  • 抗憂鬱症
  • 鴉片類藥物
  • 非麻醉性止痛藥
  • 其他

疼痛管理治療市場規模(依適應症分類)

  • 市場概況
  • 關節炎疼痛
  • 神經病變疼痛
  • 癌症痛
  • 慢性下背部疼痛
  • 術後疼痛
  • 偏頭痛
  • 纖維肌痛
  • 肌肉扭傷
  • 斷裂
  • 急性闌尾炎
  • 其他

疼痛管理治療市場規模(按分銷管道)

  • 市場概況
  • 網路藥局
  • 醫院藥房
  • 零售藥局

疼痛管理治療市場規模

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲國家
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲地區

競爭資訊

  • 前 5 家公司對比
  • 主要企業市場定位(2024年)
  • 主要市場參與者所採用的策略
  • 近期市場趨勢
  • 公司市場佔有率分析(2024 年)
  • 主要企業簡介
    • 公司簡介
    • 產品系列分析
    • 按細分市場分析市場佔有率
    • 收益與前一年同期比較(2022-2024 年)

主要企業簡介

  • CSL Behring(Australia)
  • Takeda Pharmaceutical Company Limited(Japan)
  • Pharming Group NV(Netherlands)
  • BioCryst Pharmaceuticals, Inc.(USA)
  • Ionis Pharmaceuticals, Inc.(USA)
  • Sanofi SA(France)
  • Adverum Biotechnologies, Inc.(USA)
  • KalVista Pharmaceuticals, Inc.(USA)
  • Attune Pharmaceuticals, Inc.(USA)
  • Arrowhead Pharmaceuticals, Inc.(USA)
  • Amgen Inc.(USA)
  • BioMarin Pharmaceutical Inc.(USA)
  • Catalyst Biosciences, Inc.(USA)
  • RUCONEST(Pharming Group NV, Netherlands)
  • Haegarda(CSL Limited, Australia)
  • Firazyr(Shire plc, UK)
  • Shire plc(UK)
  • Dyax Corp.(USA)
  • Adverum Biotechnologies, Inc.(USA)
  • Amgen Inc.(USA)

結論和建議

簡介目錄
Product Code: SQMIG35F2004

Global Pain Management Therapeutics Market size was valued at USD 78.7 billion in 2023 and is poised to grow from USD 81.53 billion in 2024 to USD 108.2 billion by 2032, growing at a CAGR of 3.6% during the forecast period (2025-2032).

As of October 2023, the landscape of pain management reflects a growing recognition of its importance within the medical field. Physicians increasingly turn to pain medicine specialists to implement multidisciplinary approaches that enhance patient quality of life across various types of pain, including chronic conditions like fibromyalgia, neuropathic pain, and post-operative discomfort. The rising popularity of pain management therapeutics is evident as they cater to a wide spectrum of medical issues. However, the market faces challenges as pain advocacy organizations experience diminishing influence and financial resources due to government funding cuts and decreased support from pharmaceutical sponsors. This trend poses a potential hurdle for market growth as these organizations have historically played a crucial role in advancing pain management initiatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pain Management Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pain Management Therapeutics Market Segmental Analysis

Global Pain Management Therapeutics Market is segmented by Drug Class, Indication, Distribution channel and region. Based on Drug Class, the market is segmented into NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics and Others. Based on Indication, the market is segmented into Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis and Others. Based on Distribution channel, the market is segmented into Online Pharmacy, Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pain Management Therapeutics Market

The global pain management therapeutics market is experiencing significant growth due to the increasing prevalence of various medical conditions that lead to pain and discomfort, such as ulcers, osteoarthritis, chronic arthritis, multiple sclerosis, cancer, and diabetic neuropathy. These conditions necessitate effective treatments for both acute and chronic pain, driving demand for pain management solutions. As patients seek relief from their ailments, the preference for advanced pain management therapeutics rises, further fueling market expansion. Consequently, the collective urgency to address pain-related issues across diverse populations is a crucial factor contributing to the market's robust development.

Restraints in the Global Pain Management Therapeutics Market

The growth of the Global Pain Management Therapeutics market is anticipated to be hindered by the issue of prescription drug abuse. Many individuals consume prescribed medications in a manner that deviates from medical guidance, often underestimating the potential dangers associated with such behavior. This misuse not only poses significant health risks but can also result in severe consequences, including fatal outcomes. As awareness of these dangers increases, it may lead to stricter regulations and more cautious prescribing practices, ultimately curbing the expansion of the market. Consequently, addressing the challenges posed by prescription misuse is crucial for sustainable market growth.

Market Trends of the Global Pain Management Therapeutics Market

The Global Pain Management Therapeutics market is witnessing a significant trend towards personalized medicine, with a growing focus on biologics and rapid-acting lifestyle therapies, which currently represent over 70% of all medications under development. This shift is driven by advancements in pharmacogenomics and an increased understanding of individual pain mechanisms, leading to targeted treatments that enhance efficacy and reduce side effects. Additionally, the rising prevalence of chronic pain conditions and a growing aging population are fueling demand for innovative therapies, positioning personalized approaches as a key driver in the evolution of pain management strategies globally.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Regulatory Landscape
  • Case Studies
  • Technology Analysis
  • Patent Analysis

Global Pain Management Therapeutics Market Size by Drug Class & CAGR (2025-2032)

  • Market Overview
  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics
  • Others

Global Pain Management Therapeutics Market Size by Indication & CAGR (2025-2032)

  • Market Overview
  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Muscle Sprain/Strain
  • Bone Fracture
  • Acute Appendicitis
  • Others

Global Pain Management Therapeutics Market Size by Distribution channel & CAGR (2025-2032)

  • Market Overview
  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

Global Pain Management Therapeutics Market Size & CAGR (2025-2032)

  • North America (Drug Class, Indication, Distribution channel)
    • US
    • Canada
  • Europe (Drug Class, Indication, Distribution channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Drug Class, Indication, Distribution channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Drug Class, Indication, Distribution channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Drug Class, Indication, Distribution channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • CSL Behring (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pharming Group N.V. (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioCryst Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ionis Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Adverum Biotechnologies, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • KalVista Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Attune Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arrowhead Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioMarin Pharmaceutical Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Catalyst Biosciences, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • RUCONEST (Pharming Group N.V., Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Haegarda (CSL Limited, Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Firazyr (Shire plc, UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shire plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dyax Corp. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Adverum Biotechnologies, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations